Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more
Accelerate Diagnostics Inc (AXDX) - Net Assets
Latest net assets as of March 2025: $-56.04 Million USD
Based on the latest financial reports, Accelerate Diagnostics Inc (AXDX) has net assets worth $-56.04 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.56 Million) and total liabilities ($84.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-56.04 Million |
| % of Total Assets | -196.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -142.13% |
| Growth Volatility | 102.0 |
Accelerate Diagnostics Inc - Net Assets Trend (1996–2024)
This chart illustrates how Accelerate Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Accelerate Diagnostics Inc (1996–2024)
The table below shows the annual net assets of Accelerate Diagnostics Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-56.04 Million | -181.78% |
| 2023-12-31 | $-19.89 Million | +10.67% |
| 2022-12-31 | $-22.26 Million | +36.52% |
| 2021-12-31 | $-35.07 Million | +44.17% |
| 2020-12-31 | $-62.81 Million | -751.23% |
| 2019-12-31 | $-7.38 Million | -112.86% |
| 2018-12-31 | $57.38 Million | -52.16% |
| 2017-12-31 | $119.92 Million | +54.11% |
| 2016-12-31 | $77.82 Million | -41.50% |
| 2015-12-31 | $133.02 Million | +101.57% |
| 2014-12-31 | $65.99 Million | +58.95% |
| 2013-12-31 | $41.52 Million | +179.85% |
| 2012-12-31 | $14.84 Million | +208.08% |
| 2011-12-31 | $4.82 Million | -1.92% |
| 2010-12-31 | $4.91 Million | +26.07% |
| 2009-12-31 | $3.89 Million | -11.75% |
| 2008-12-31 | $4.41 Million | -9.57% |
| 2007-12-31 | $4.88 Million | -27.59% |
| 2006-12-31 | $6.74 Million | -30.29% |
| 2005-12-31 | $9.67 Million | -17.62% |
| 2004-12-31 | $11.74 Million | -7.80% |
| 2003-12-31 | $12.73 Million | -7.39% |
| 2002-12-31 | $13.74 Million | +43.00% |
| 2001-12-31 | $9.61 Million | -14.66% |
| 2000-12-31 | $11.26 Million | -7.96% |
| 1999-12-31 | $12.24 Million | -0.97% |
| 1998-12-31 | $12.36 Million | +34.30% |
| 1997-12-31 | $9.20 Million | +384.21% |
| 1996-12-31 | $1.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Accelerate Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71879900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-6.00K | % |
| Other Components | $662.87 Million | % |
| Total Equity | $-56.04 Million | 100.00% |
Accelerate Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Accelerate Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kopp Glass Inc
PINK:KOGL
|
$539.05K |
|
Sorrento Therape
OTCQB:SRNE
|
$539.11K |
|
LAS VEGAS SANDS
BE:LCR
|
$539.29K |
|
ARROWHEAD RESEARCH
BE:HDP1
|
$539.59K |
|
Alaska Power & Telephone Company
PINK:APTL
|
$538.24K |
|
LIFECLEAN INTL AB
F:651
|
$538.19K |
|
STERICYCLE (SY9.SG)
STU:SY9
|
$537.74K |
|
Awareness Group
NASDAQ:TAAG
|
$537.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Accelerate Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -19,888,000 to -56,040,000, a change of -36,152,000.
- Net loss of 50,045,000 reduced equity.
- New share issuances of 29,982,000 increased equity.
- Other comprehensive income increased equity by 606,000.
- Other factors decreased equity by 16,695,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.05 Million | -89.3% |
| Share Issuances | $29.98 Million | +53.5% |
| Other Comprehensive Income | $606.00K | +1.08% |
| Other Changes | $-16.70 Million | -29.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Accelerate Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $3.46 | $0.04 | x |
| 1997-12-31 | $11.04 | $0.04 | x |
| 1998-12-31 | $15.21 | $0.04 | x |
| 1999-12-31 | $15.23 | $0.04 | x |
| 2000-12-31 | $14.50 | $0.04 | x |
| 2001-12-31 | $12.52 | $0.04 | x |
| 2002-12-31 | $16.44 | $0.04 | x |
| 2003-12-31 | $13.38 | $0.04 | x |
| 2004-12-31 | $11.78 | $0.04 | x |
| 2005-12-31 | $9.71 | $0.04 | x |
| 2006-12-31 | $6.76 | $0.04 | x |
| 2007-12-31 | $4.90 | $0.04 | x |
| 2008-12-31 | $4.39 | $0.04 | x |
| 2009-12-31 | $3.81 | $0.04 | x |
| 2010-12-31 | $4.72 | $0.04 | x |
| 2011-12-31 | $4.46 | $0.04 | x |
| 2012-12-31 | $11.90 | $0.04 | x |
| 2013-12-31 | $11.04 | $0.04 | x |
| 2014-12-31 | $15.13 | $0.04 | x |
| 2015-12-31 | $29.56 | $0.04 | x |
| 2016-12-31 | $15.18 | $0.04 | x |
| 2017-12-31 | $22.18 | $0.04 | x |
| 2018-12-31 | $10.53 | $0.04 | x |
| 2019-12-31 | $-1.35 | $0.04 | x |
| 2020-12-31 | $-11.21 | $0.04 | x |
| 2021-12-31 | $-5.68 | $0.04 | x |
| 2022-12-31 | $-3.61 | $0.04 | x |
| 2023-12-31 | $-1.59 | $0.04 | x |
| 2024-12-31 | $-2.40 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Accelerate Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -427.81%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-19.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 57.89% | 52.38% | 0.91x | 1.21x | $910.00K |
| 1997 | 10.87% | 40.00% | 0.26x | 1.07x | $80.00K |
| 1998 | 23.30% | 39.00% | 0.53x | 1.13x | $1.64 Million |
| 1999 | 0.58% | 2.43% | 0.21x | 1.15x | $-1.15 Million |
| 2000 | -8.19% | -58.86% | 0.12x | 1.16x | $-2.05 Million |
| 2001 | -16.09% | -180.76% | 0.08x | 1.12x | $-2.51 Million |
| 2002 | -2.92% | -61.28% | 0.04x | 1.09x | $-1.78 Million |
| 2003 | -10.81% | -161.75% | 0.06x | 1.08x | $-2.65 Million |
| 2004 | -7.75% | -766.71% | 0.01x | 1.08x | $-2.08 Million |
| 2005 | -21.63% | -416.40% | 0.05x | 1.14x | $-3.06 Million |
| 2006 | -44.97% | -1424.83% | 0.03x | 1.16x | $-3.70 Million |
| 2007 | -39.43% | -1050.75% | 0.03x | 1.26x | $-2.41 Million |
| 2008 | -38.08% | -353.37% | 0.08x | 1.32x | $-2.12 Million |
| 2009 | -18.34% | -56.24% | 0.24x | 1.34x | $-1.10 Million |
| 2010 | 13.07% | 28.58% | 0.36x | 1.28x | $150.77K |
| 2011 | -7.87% | -33.78% | 0.18x | 1.30x | $-860.31K |
| 2012 | -35.80% | -2250.42% | 0.01x | 1.16x | $-6.79 Million |
| 2013 | -36.81% | -31649.21% | 0.00x | 1.05x | $-19.43 Million |
| 2014 | -46.87% | -25354.92% | 0.00x | 1.06x | $-37.53 Million |
| 2015 | -34.20% | -30951.02% | 0.00x | 1.05x | $-58.80 Million |
| 2016 | -85.30% | -26981.30% | 0.00x | 1.06x | $-74.16 Million |
| 2017 | -52.44% | -1505.43% | 0.03x | 1.06x | $-74.87 Million |
| 2018 | -153.95% | -1557.78% | 0.03x | 3.23x | $-94.06 Million |
| 2019 | 0.00% | -906.80% | 0.07x | 0.00x | $-83.57 Million |
| 2020 | 0.00% | -700.47% | 0.12x | 0.00x | $-71.93 Million |
| 2021 | 0.00% | -659.50% | 0.14x | 0.00x | $-74.19 Million |
| 2022 | 0.00% | -490.06% | 0.20x | 0.00x | $-60.27 Million |
| 2023 | 0.00% | -510.97% | 0.38x | 0.00x | $-59.63 Million |
| 2024 | 0.00% | -427.81% | 0.41x | 0.00x | $-44.44 Million |
Industry Comparison
This section compares Accelerate Diagnostics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Accelerate Diagnostics Inc (AXDX) | $-56.04 Million | 57.89% | N/A | $538.57K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |